Transparency Market Research (TMR) has published a new report titled, “Prescription Dermatology Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global prescription dermatology therapeutics market was valued at US$ 27,580.0 Mn in 2017 and is projected to expand at a CAGR of 9.5% from 2018 to 2026. High prevalence of chronic dermatological disorders, large unmet medical needs, and new product approvals are anticipated to drive the global market in the next few years.
North America is expected to dominate the global prescription dermatology therapeutics market during the forecast period, followed by Europe. Potential unmet medical needs for moderate to severe psoriasis and skin cancer, increase in adoption of biologic drugs, and new product approvals & launches in the U.S. and Europe are likely to drive the prescription dermatology therapeutics market in these regions during the forecast period. The market in Asia Pacific is projected to expand at a high CAGR during the forecast period.
High prevalence and rise in incidence rate of various chronic as well as acute dermatological disorders across the globe are the key factors driving the global prescription dermatology therapeutics market. According to the World Health Organization (WHO), over 900 million people were affected with skin diseases in 2017, and the five most common skin disorders account for around 80% of the skin disorders. Atopic dermatitis, a common and chronic inflammatory skin disease, affects 15% to 20% children and 1% to 3% adults across the world. According to the WHO, 2 million to 3 million patients are affected by non-melanoma skin cancer and around 132,000 melanoma skin cancers occur across the world each year. Hence, rise in incidence rate of dermatological disorders across the globe and increase in awareness about various skin diseases are projected to propel the global prescription dermatology therapeutics market during the forecast period.
Request to View Sample of Report -
The report offers a detailed segmentation of the global prescription dermatology therapeutics market based on different prescription dermatology therapeutic products approved and commercialized for dermatological indications. Based on product type, the global market has been segmented into acne & rosacea drugs, psoriasis drugs, dermatitis & seborrhea drugs, fungal infection drugs, skin cancer drugs, and others. High prevalence of psoriasis and significant rise in number of psoriasis patients across the globe are projected to fuel the growth of the psoriasis drugs segment during the forecast period.
According to the International Federation of Psoriasis Associations, over 125 million people were affected with psoriasis globally in 2015. Moreover, various studies have shown that between 10% and 30% of patients with psoriasis tend to develop psoriatic arthritis. Furthermore, most of the biologic drugs are approved for the treatment of only psoriasis. High adoption of biologic drugs in the developed markets contributed to high share of the psoriasis drugs segment in 2017. Promising biologic product pipeline for psoriasis treatment and anticipated commercialization of the late stage clinical biologic products are likely to augment the psoriasis drugs segment during the forecast period.
Comments
Post a Comment